Cimerli Injection, Solution
Product Images NDC 61314-625

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Cimerli (NDC 61314-625). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sandoz Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Image (Cimerli 01)

Image (Cimerli 01)
FDA Label Image

Image (Cimerli 02)

Image (Cimerli 02)
FDA Label Image

Image (Cimerli 03)

Image (Cimerli 03)
FDA Label Image

Image (Cimerli 04)

Image (Cimerli 04)
FDA Label Image

Image (Cimerli 05)

Image (Cimerli 05)
FDA Label Image

Figure 1 (Cimerli 06)

Figure 1 (Cimerli 06)
FDA Label Image

Figure 2 (Cimerli 07)

Figure 2 (Cimerli 07)
FDA Label Image

Figure 3 (Cimerli 08)

Figure 3 (Cimerli 08)
This is a list that includes information about different dosages of a medication called Ranizumab. It appears to compare two different doses of 0.5 mg and 0.05 mg. It also mentions the frequency of usage.*
FDA Label Image

Figure 4 (Cimerli 09)

Figure 4 (Cimerli 09)
FDA Label Image

Figure 5 (Cimerli 10)

Figure 5 (Cimerli 10)
FDA Label Image

Figure 6 (Cimerli 11)

Figure 6 (Cimerli 11)
FDA Label Image

Figure 7 (Cimerli 12)

Figure 7 (Cimerli 12)
FDA Label Image

Figure 8 (Cimerli 13)

Figure 8 (Cimerli 13)
This text provides information on the Percentage of Eyes (upper 95% CI) over a 2-year period for individuals with baseline diabetic macular edema (DME) and those without. It includes data on the percentage of eyes showing a 3-step improvement in the first year compared to the second year. The table also shows the numbers of eyes in each category for a comprehensive analysis.*
FDA Label Image

Figure 9 (Cimerli 14)

Figure 9 (Cimerli 14)
FDA Label Image

0.3mg Vial Carton (Cimerli 15)

0.3mg Vial Carton (Cimerli 15)
This text contains information about a medication named ranibizumab (brand name not provided) used for the treatment of Diabetic Macular Edema and Diabetic Retinopathy. The medication is available in a single-dose glass vial. The provided National Occupational Classification (NOC) number is 61314624-94.*
FDA Label Image

0.5mg Vial Carton (Cimerli 16)

0.5mg Vial Carton (Cimerli 16)
This text is a description of a medication called CIMERLI. It contains ranibizumab equivalent to 5mg, and it is administered via intravitreal injection. The medication is indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, and myopic choroidal neovascularization. The package includes a single-dose glass vial and prescribing information. This medication is for prescription use only.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.